The Rise of Clean Label and Natural Ingredients The trend towards organic and natural products has been growing steadily over the years. Consumers are increasingly looking for products that are free from synthetic ingredients and have a cleaner label. …
Excipient-Free Alternatives: What Are the Options? Read Post »
Annual Drug Patent Expirations for QLOSI Qlosi is a drug marketed by Orasis Pharms and is included in one NDA. […]
Source
Annual Drug Patent Expirations for TLANDO Tlando is a drug marketed by Verity and is included in one NDA. It […]
Source
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
This chart shows the companies which have received the most New Combination exclusivities in the past five years. New Combinations […]
Source
Pharmaceutical companies with the most ‘New Combination’ drugs Read Post »
Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process. However, by following […]
Source
Genetic engineering has been a crucial component of biotechnology for decades, and its future holds immense promise. From gene therapy
The Future of Genetic Engineering: Biotechnology’s Role Explained Read Post »
Selecting the right binder excipient is a critical step in pharmaceutical formulation. Binders play a crucial role in ensuring the cohesiveness of the tablet, impacting its mechanical strength, disintegration, and overall efficacy. This article delves …
XEGLYZE (abametapir) Hatchtech Patent: 8,212,038 Expiration: Jul 16, 2024 See More … For more information on how DrugPatentWatch can help […]
Source
Drug Patent Expirations for the Week of July 14, 2024 Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Get new actionable insights and updates from BiotechBlog
